Heron Therapeutics (HRTX) investor relations material

Opening remarks and agenda

• The meeting was called to order by the CEO, with the CFO and VP of Legal present; the Inspector of Elections was appointed.

• The meeting was held virtually to increase access and participation, and stockholders could submit questions related to proposals.

• Notice of the meeting and proxy materials were distributed to all eligible stockholders, with 188,638,866 shares outstanding and entitled to vote.

Board and executive committee updates

• Seven director nominees were presented for election to serve until the 2027 annual meeting or until their successors are qualified.

Shareholder proposals

• Six proposals were presented: election of directors, ratification of the independent auditor, advisory approval of executive compensation, amendments to the equity incentive and employee stock purchase plans, and ratification of the Tax Benefits Preservation Plan.